potassium iodide
Trade name: thyro-block
Approved
Jun 1, 1973
Potassium iodide is a chemical compound, medication, and dietary supplement. It is a medication used for treating hyperthyroidism, in radiation emergencies, and for protecting the thyroid gland when certain types of radiopharmaceuticals are used. It is also used for treating skin sporotrichosis and phycomycosis. It is a supplement used by people with low dietary intake of iodine. It is administered orally. — Wikipedia
Clinical trial activity
24 trials · 39 clinical orgs · 8 marketing orgs
Earliest trial started May 1, 2004 (NCT00277589)
Timeline
1970s
- Jun 1, 1973
Earliest FDA Approval
- Nov 9, 1979
Meda Pharmaceuticals — First NDA Organization
- Nov 9, 1979
Meda Pharmaceuticals — NDA Secondary Org
- Nov 9, 1979
Meda Pharmaceuticals — NDA Organization
1980s
- Feb 19, 1982
Roxane Laboratories — NDA Secondary Org
- Feb 19, 1982
Boehringer Ingelheim — NDA Secondary Org
- Oct 14, 1982
Anbex — NDA Secondary Org
2000s
- Sep 10, 2002
Recipharm — Marketing Organization
- Sep 10, 2002
BTG — Marketing Organization
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
- Jan 12, 2005
Arco Pharms Llc — Marketing Organization
- Jan 1, 2006
Earliest Phase 3 Sponsor(trial)
2010s
- Mar 24, 2016
Mission Pharmacal — Marketing Organization
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Studied for
- Dental Caries · Phase 4
- Dentin Sensitivity · Phase 2/Phase 3
- Ependymoma · Phase 2
- Goiter, Nodular · Phase 4
- Graves Disease · Phase 4
- Heart Failure · Phase 3
- Hyperthyroidism · Phase 4
- Infant, Premature, Diseases · Phase 3
- Lymphoma · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Medulloblastoma · Phase 2
- Neoplasm Metastasis · Early Phase 1
- Neuroblastoma · Early Phase 1
- Orthodontic Appliances, Fixed · Phase 2
- Pregnancy · Phase 3
- Tooth Abnormalities · Phase 2
- Tooth Demineralization · Phase 2
Mechanism of action
- Unspecified targetOTHER
Unknown
Iodine seems to lead to protein precipitation
Approval history
- approvedJun 1, 1973
Chemistry & pharmacology
SMILES
[I-]- Mol. weight
- 126.90447 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- Yes
- Polymer
- No
- Delivery
- Oral
- Availability
- Over the Counter
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaPotassium iodide ↗
- NCATS09G4I6V86Q ↗
- ChEMBLCHEMBL1141 ↗
Also known as
- iodide
- iodide
- iodide
- iodide
- iodide ion
- iodide ion
- iosat
- iosat
- jodetten depot
- kaliumiodid
- kaliumiodid
- kalium iodidum
- kaliumjodid
- kaliumjodid
- ki
- ki
- potassium iodide
- potassium iodide
- potassium iodide
- potassium iodide
- potassium iodide
- potassium iodide
- potassium iodide
- potassium iodide
- potassium iodide
- potassium iodide
- potassium monoiodide
- pot iodide ammoniat
- thyro-block
- thyro-block
- thyrosafe
- thyrosafe
- thyroshield
- thyroshield
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06797882 | Phase 2 | Jan 31, 2025 | National University of Malaysia |
| NCT06699199 | Phase 4 | Nov 1, 2023 | King Abdul-Aziz University |
| NCT05628506 | N/A | Jan 1, 2023 | University of Lausanne |
| NCT04743661 | Phase 2 | Oct 1, 2021 | Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI), Pediatric Brain Tumor Consortium, Y-Mabs, Inc |
| NCT04856488 | Phase 3 | Aug 31, 2021 | Karolinska Institute |
| NCT04816487 | N/A | May 1, 2021 | Cairo University |
| NCT04867291 | N/A | Apr 30, 2021 | University of Glasgow |
| NCT04196829 | Phase 4 | Jan 31, 2020 | Cairo University |
| NCT04804423 | Phase 2/Phase 3 (Phase 3) | Jan 13, 2020 | SDI Limited, University of Greifswald |
| NCT05296213 | N/A | Dec 1, 2019 | Mansoura University |
| NCT03649438 | Early Phase 1 (Phase 1) | Sep 4, 2018 | The University of Texas, Dallas |
| NCT03377218 | N/A | Jan 5, 2018 | Latvian Biomedical Research and Study Centre, Latvian Institute of Organic Synthesis, Riga Maternity hospital, Riga Stradins University |
| NCT02656329 | Phase 3 | Jan 1, 2016 | General Electric, ICON, TFS Trial Form Support |
| NCT02771704 | N/A | Oct 31, 2015 | Kuwait University |
| NCT04080505 | Phase 3 | Feb 10, 2015 | Columbia University |
| NCT02103998 | Phase 3 | Jul 1, 2014 | National Institute of Neurological Disorders and Stroke (NINDS), New York Medical College |
| NCT01850888 | N/A | Dec 1, 2013 | University of Minnesota |
| NCT03889431 | N/A | Jan 2, 2013 | Central Washington University, Oklahoma State University |
| NCT02360124 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2012 | The University of Hong Kong |
| NCT00490490 | Phase 2 | Jan 1, 2007 | GlaxoSmithKline, Stanford University |
Organizations
Research & Development (39)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cairo University | Academic/Hospital | 2 | 2 | 2 | 2020 |
| GlaxoSmithKline | For profit | 2 | 0 | 1 | 2004 |
| Stanford University | Academic/Hospital | 2 | 2 | 1 | 2004 |
| Aix-University of Marseille | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Central Washington University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Columbia University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Corixa | For profit | 1 | 0 | 1 | 2004 |
| General Electric | For profit | 1 | 1 | 1 | 2016 |
| Government of France | Government | 1 | 0 | 1 | 2006 |
| ICON | For profit | 1 | 0 | 1 | 2016 |
| Karolinska Institute | Academic/Hospital | 1 | 1 | 1 | 2021 |
| King Abdul-Aziz University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Kuwait University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Latvian Biomedical Research and Study Centre | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Latvian Institute of Organic Synthesis | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Mansoura University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2021 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2021 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 0 | 1 | 2014 |
| National University of Malaysia | Academic/Hospital | 1 | 1 | 1 | 2025 |
Marketing (10)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Anbex | For profit | NDA2 | Oct 14, 1982 |
| Arco Pharms Llc | For profit | MKTG | Jan 12, 2005 |
| BTG | For profit | MKTG | Sep 10, 2002 |
| Boehringer Ingelheim | For profit | NDA2 | Feb 19, 1982 |
| Meda Pharmaceuticals | For profit | NDA2 | Nov 9, 1979 |
| Meda Pharmaceuticals | For profit | NDA | Nov 9, 1979 |
| Mission Pharmacal | For profit | MKTG | Mar 24, 2016 |
| Mission Pharmacal | For profit | SYN | Mar 24, 2016 |
| Recipharm | For profit | MKTG | Sep 10, 2002 |
| Roxane Laboratories | For profit | NDA2 | Feb 19, 1982 |